Intervention 1: Intervention group: Routine treatment plus tablet Empagliflozin 10 mg (manufactured by Abidi Pharmaceutical Co.) daily for 3 months. Intervention 2: Control group: Routine treatment pl

2 trials

Sponsors

Hamedan University of Medical Sciences

Conditions

Systolic heart failure. Systolic (congestive) heart failure

Phase 3

Effect of Empagliflozin as adjunctive therapy versus placebo on serum level of oxidative stress biomarkers in diabetic patients with systolic heart failure

Active, not recruitingIRCT20120215009014N484

Hamedan University of Medical SciencesSystolic heart failure. Systolic (congestive) heart failure

Start: 2023-10-23Target: 80Updated: 2023-10-16

Effect of Empagliflozin as adjunctive therapy on serum level of oxidative stress biomarkers

Active, not recruitingIRCT20120215009014N486

Hamedan University of Medical SciencesSystolic heart failure. Systolic (congestive) heart failure

Start: 2023-10-23Target: 80Updated: 2023-10-16

Related Papers

Empagliflozin Ameliorates the Oxidative Stress Profile in Type 2 Diabetic Patients with Heart Failure and Reduced Ejection Fraction: Results of a Randomized, Double-blind, Placebo-controlled Study

Reviews on Recent Clinical Trials2025-01-085 citations